Doximity’s Dip: A Spot of Bother, But Nothing a Good Analyst Can’t Sort

Right then, a bit of a kerfuffle on the market today, what with Doximity – the digital platform for medical chaps, you know – experiencing a rather noticeable dip. Shares, it seems, have taken a tumble of 24% as of this morning, following the announcement of their quarterly earnings. A dashedly awkward moment, one might think. However, before reaching for the smelling salts, let’s have a look at the particulars. The earnings themselves weren’t too dreadful, exceeding the expectations of those Wall Street gentlemen, but it was the guidance for the next quarter – a mere 4% growth in revenue – that sent a shiver through the market. A bit on the cautious side, wouldn’t you agree?

The sales figures, you see, have been slowing down. From a brisk 23% last year to a rather more sedate 10% this quarter. A bit like a promising racehorse losing its steam, what? And this cautious forecast has understandably ruffled a few feathers. To add to the general air of mild panic, net income has dipped from a respectable $75 million to $62 million, thanks to a rather enthusiastic splurge on marketing and a significant investment in their artificial intelligence infrastructure. One can’t have everything, of course, but it does present a bit of a puzzle.

Now, before one starts imagining a complete financial catastrophe, it’s worth pointing out that much of this volatility is merely short-term bother. The pharmaceutical companies, you see, are rather large customers of Doximity, utilising the platform for advertising. These chaps have been grappling with their own industry headwinds, and sixteen of the twenty largest firms recently signed these “most-favoured-nation” agreements. A bit of bureaucratic muddle, really, causing a delay in bookings with Doximity. Tim Cabral, a board member of considerable sense, assures us this is merely a timing issue, and January’s bookings growth is, in fact, the best they’ve seen since going public. A most reassuring observation, wouldn’t you say? So, the slowdown in the last quarter or two shouldn’t be taken as a harbinger of doom.

And what of this artificial intelligence investment? Currently, it’s proving a bit of a drain on the finances, but the adoption rates are most promising. Over 100 of the top U.S. health systems are now utilising Doximity’s AI products, with over 300,000 prescribers on board. A truly impressive figure! The company hasn’t included any AI revenue in their guidance yet, but as they fully launch and monetize their commercial AI suite later this year, one anticipates a rather handsome improvement in growth rates and margins. Currently trading at just 17 times free cash flow, and used by a staggering 85% of U.S. physicians – and two-thirds of physician assistants and nurse practitioners – Doximity, despite this little wobble, remains a most promising growth stock. A spot of bother, certainly, but nothing a good analyst – or a particularly clever bit of code – can’t sort out. I, for one, shall be looking to add to my holdings presently.

2026-02-06 19:53

Read More